Company intelligence / Profile preview
Forest Hills Lab
Hong Kong, Hong Kongforesthillslab.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Forest Hills Lab is advancing a multi-modal pipeline of seven potentially disease-modifying neurological assets. Lead programs target Parkinson's and Alzheimer's diseases. Clinical progress includes an IND-approved new chemical entity entering Phase 1, another candidate nearing Phase 2 for Parkinson's, and preclinical evidence showing reduction of alpha-synuclein and amyloid-beta in animal models.[4][5]
- Therapeutic areas
- Neurology
- Modalities
- Small molecules[5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Rush University – licensing multiple candidates from Dr. Kalipada Pahan's lab at Rush University Medical Center.[5]
Beyond the preview
Go deeper on Forest Hills Lab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forest Hills Lab.